Depression-like phenotype following chronic CB1 receptor antagonism

Depression-like phenotype following chronic CB1 receptor antagonism

Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately, CB1 receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically, we investigated the effects of rimonabant in rodent...

Full description

Bibliographic Details
Main Authors: Chad E. Beyer, Jason M. Dwyer, Michael J. Piesla, Brian J. Platt, Ru Shen, Zia Rahman, Karen Chan, Melissa T. Manners, Tarek A. Samad, Jeffrey D. Kennedy, Brendan Bingham, Garth T. Whiteside
Format: Article
Language:English
Published: Elsevier 2010-08-01
Series:Neurobiology of Disease
Subjects:
Cannabinoids
Rimonabant
Mood disorders
Chronic mild stress
Neurogenesis
Cytokines
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110000926

Internet

http://www.sciencedirect.com/science/article/pii/S0969996110000926

Similar Items